Annual report pursuant to Section 13 and 15(d)

Income Taxes - Schedule of Components of Deferred Tax Assets (Details)

v3.24.1
Income Taxes - Schedule of Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets:    
Net operating loss carryforwards $ 37,231 $ 60,952
Research and development credits 32,800 40,396
Capitalized research and development expenditure 46,260 24,481
Deferred royalty obligation 31,944  
Deferred revenue 15,274  
Accruals and other 5,309 3,849
Operating lease liability 6,335 7,471
Stock based compensation 5,613 4,562
Fixed asset basis   663
Total deferred tax assets 180,766 142,374
Less: valuation allowance (167,693) (131,228)
Gross deferred tax assets 13,073 11,146
Deferred tax liabilities:    
Operating lease right-of-use asset (4,887) (5,783)
Fixed asset basis (809)  
Vaxcyte investment (7,377) (5,363)
Total deferred tax liabilities (13,073) (11,146)
Total net deferred tax assets $ 0 $ 0